Sugi Predict

Sugi Predict / Compounds / SCHEMBL330293

SCHEMBL330293

SCHEMBL330293

COC(=O)c1cc(S(N)(=O)=O)ccc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.72
▸ CA2 P00918 8/20 0.58
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ YAP1 P46937 1/20 0.54
▸ CA9 Q16790 3/20 0.51
▸ CA12 O43570 3/20 0.51
▸ CA1 P00915 3/20 0.51
▸ CA14 Q9ULX7 2/20 0.51
▸ PTGS1 P23219 2/20 0.50
▸ DRD2 P14416 2/20 0.50
▸ DRD1 P21728 2/20 0.50
▸ DRD4 P21917 2/20 0.50
▸ DRD3 P35462 2/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ CA3 P07451 1/20 0.50
▸ ADRA2A P08913 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7413111 0.86 GAA (0.56) GAACA2MEN1KMT2AYAP1
SCHEMBL11408239 0.85 GAA (0.65) GAACA2MEN1KMT2ACA9
SCHEMBL17665814 0.85 GAA (0.54) GAAMEN1KMT2ALMNATSHR
SCHEMBL131628 0.85 GAA (0.65) GAACA2MEN1KMT2ACA9
SCHEMBL29598834 0.85 GAA (0.65) GAACA2MEN1KMT2ACA9
SCHEMBL3220624 0.85 SMN1; SMN2 (0.57) GAAMEN1KMT2ADRD2DRD3
SCHEMBL7144405 0.85 GAA (0.65) GAACA2MEN1KMT2ACA9
SCHEMBL10723872 0.85 GAA (0.78) GAACA2MEN1KMT2ACA9
SCHEMBL7257671 0.84 GAA (0.64) GAACA2MEN1KMT2ACA9
SCHEMBL15352924 0.84 GAA (0.52) GAAMEN1KMT2ADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114965749-B Detection method of related substances in Shubian bulk drug 南京海纳医药科技股份有限公司 2024-09-03 — — CN claimed
CN-116693438-A Synthesis process of sulpride 焦作福瑞堂制药有限公司 2023-09-05 — — CN claimed
CN-111100042-B Preparation method of 2-methoxy-5-sulfonamide benzoic acid 苏州诚和医药化学有限公司 2022-05-31 — — CN claimed
CN-112441960-B Synthetic method of sulpiride 常州康普药业有限公司 2022-03-01 — — CN claimed
CN-112441960-A Synthetic method of sulpiride 常州康普药业有限公司 2021-03-05 — — CN claimed
CN-111100042-A Preparation method of 2-methoxy-5-sulfonamide benzoic acid 苏州诚和医药化学有限公司 2020-05-05 — — CN claimed
US-20070105201-A1 Process for the enantiomeric resolution of 1-substituted 2-(aminomethyl)-pyrrolidines by amidation in the presence of lipases PROCOS S.P.A. (IT) 2007-05-10 — — US claimed
EP-1775347-A2 A process for the enantiomeric resolution of 1-substituted 2-(aminomethyl)-pyrrolidines by amidation with lipases Procos S.p.A. (IT) 2007-04-18 — — EP claimed
CN-114965749-B Detection method of related substances in Shubian bulk drug 南京海纳医药科技股份有限公司 2024-09-03 — — CN disclosed
CN-118496140-A Refining method of sulpiride 杭州国瑞生物科技有限公司 2024-08-16 — — CN disclosed
CN-116693438-A Synthesis process of sulpride 焦作福瑞堂制药有限公司 2023-09-05 — — CN disclosed
CN-116693438-A Synthesis process of sulpride 焦作福瑞堂制药有限公司 2023-09-05 — — CN disclosed
CN-111574420-B Preparation method of aminopyrrolidine 北京石油化工学院 2022-09-20 — — CN disclosed
CN-114965749-A Detection method of related substances in sulpiride bulk drug 南京海纳医药科技股份有限公司 2022-08-30 — — CN disclosed
US-20060122243-A1 Antiallergic INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-06-08 — — US disclosed
US-20060100257-A1 Inhibitors against the activation of ap-1 and nfat INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-05-11 — — US disclosed
US-20060014811-A1 Medicament for treatment of cancer INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-01-19 — — US disclosed
US-4935511-A Nervous system, gastrointestinal disorders RORER PHARMACEUTICAL CORPORATION (US) 1990-06-19 — — US disclosed
US-4673686-A CNS MODIFIERS, ANTI-APOMORPHINE ANTIENETIC ACITIVTY/ SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLE DE L'ILE DE FRANCE (FR) 1987-06-16 — — US disclosed
US-3950527-A SEDATIVES ROUSSEL-UCLAF (FR) 1976-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014811-A1 Medicament for treatment of cancer HDAC3, HDAC1, HDAC6 GAA 919/4885CA2 345/4885MEN1 3560/4885
US-20060122243-A1 Antiallergic EPX, NAT1, HNMT GAA 1436/4885CA2 191/4885MEN1 2381/4885
US-20060100257-A1 Inhibitors against the activation of ap-1 and nfat NFATC1, AP1G1, ATF1 GAA 1702/4885CA2 509/4885MEN1 4737/4885
US-20070105201-A1 Process for the enantiomeric resolution of 1-substituted 2-(aminomethyl)-pyrrolidines by amidation in the presence of lipases CES2, APEH, LPL GAA 166/4885CA2 1668/4885MEN1 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.